P686: A PHASE 1 FIRST IN-HUMAN STUDY OF BGB-16673, A BRUTON TYROSINE KINASE PROTEIN DEGRADER, IN PATIENTS (PTS) WITH B-CELL MALIGNANCIES (TRIAL IN PROGRESS)

• C. S. Tam,
• C. Cheah,
• D. A. Stevens,
• K. By,
• X. Chen,
• B. Tariq,
• G. S. Vosganian,
• J. Huang,
• M. Alwan

Affiliations

C. S. Tam

1 Peter MacCallum Cancer Centre, Melbourne, Victoria

C. Cheah

4 Department of Haematology, Sir Charles Gairdner Hospital and Pathwest Laboratory Medicine, Nedlands, Western Australia

D. A. Stevens

7 Norton Cancer Institute, Louiseville, KY

K. By

8 BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, United States of America

X. Chen

8 BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, United States of America

B. Tariq

8 BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, United States of America

G. S. Vosganian

8 BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, United States of America

J. Huang

8 BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, United States of America

M. Alwan

9 Perth Blood Institute, West Perth, Western Australia, Australia